PS
RNAM

Principal Securities’s Avidity Biosciences RNAM Stock Holding History

Principal Securities’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-491
Closed -$21.4K – 3066
2025
Q3 		$21.4K Buy
491
+374
+320% +$15.1K ﹤0.01% 2372
2025
Q2 		$3.32K Buy
117
+72
+160% +$2.15K ﹤0.01% 2990
2025
Q1 		$1.31K Hold
45
– – ﹤0.01% 3150
2024
Q4 		$1.31K Buy
45
+9
+25% +$376 ﹤0.01% 3144
2024
Q3 		$1.65K Buy
+36
New +$1.56K ﹤0.01% 3007

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Principal Securities's RNAM Position: Q4 2025 in Review

Principal Securities sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 491 shares — an estimated $21.4K sold.

Principal Securities first reported a position in RNAM in Q3 2024 and held it in 5 quarters. The position peaked at $21.4K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Principal Securities reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 491 Avidity Biosciences shares in Q4 2025, an estimated $21.4K.
  • Principal Securities first reported a position in Avidity Biosciences in Q3 2024 and held it in 5 quarters.
  • Principal Securities's Avidity Biosciences position peaked at $21.4K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.